Kennedy Disease - 17 Studies Found

Active, not recruiting : Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer
: Advanced, Androgen Receptor Positive Triple Negative Breast Cancer
: 2013-06-26
: Drug: Enzalutamide 160 mg administered as four soft gelatin capsules orally once daily
Completed : Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors
: Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor
: 2014-04-29
: Drug: AZD5312 AZD5312 is a generation 2.5 antisense oligonucleotide (ASO) which is designed with the pur
Terminated : A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT)
:
  • Metastatic Breastcancer
  • Estrogen Receptor Positive Breast Cancer
  • Androgen Receptor Positive
  • Estrogen Receptor Negative
  • : 2016-11-21
    :
    • Drug: Enobosarm Given PO
Recruiting : A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer
: Prostate Cancer
: 2015-07-06
:
  • Drug: LY2452473 LY2452473 is a
Not yet recruiting : Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
:
  • Castration-Resistant Prostatic Cancer
  • Metastatic Prostate Carcinoma
  • Biological: GnRH agonist/antagonist

Completed : Genetic Polymorphism of the Androgen Receptor-Gene and Sexual Function in Middle Aged Women
:
  • Libido
  • Receptors, Androgen
  • Polymorphism, Genetic
  • : 2013-10-30
Recruiting : Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers
: Salivary Cancer
: 2016-04-21
: Drug: enzalutamide oral
Withdrawn : STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling
: Adenocarcinoma of the Prostate
: 2011-04-21
:
  • Drug: STA9090 200 mg/m^2 IV ev
Recruiting : Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
: Metastatic Breast Cancer
: 2013-11-08
: Drug: Orteronel Other Name: Tak-700
Next >>>